Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on 10x Genomics (NASDAQ:TXG) and increased the price target from $45 to $55, indicating a positive outlook on the company's stock.
January 25, 2024 | 2:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on 10x Genomics and raises the price target from $45 to $55, suggesting a bullish stance on the stock.
The increase in price target by Barclays reflects a positive assessment of 10x Genomics' prospects, likely leading to increased investor confidence and potential short-term stock price appreciation.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100